International Center for Genetic Engineering and Biotechnology
International Center for Genetic Engineering and Biotechnology
Genethon and International Center For Genetic Engineering And Biotechnology | Date: 2015-04-27
The invention relates to a nucleic acid sequence useful in the treatment of hyperbilirubinemia, in particular in the treatment of Crigler-Najjar syndrome. More particularly, the nucleic acid sequence of the present invention is a codon-optimized UGT1A1 coding sequence.
International Center For Genetic Engineering And Biotechnology | Date: 2017-07-12
The invention provides a recombinant polypeptide comprising the EDIII domain of each of Dengue virus serotype DENV-1, DENV-2, DENV-3, and DENV-4linked to the N-terminal of HBsAg.
SUN PHARMACEUTICAL INDUSTRIES Ltd and International Center For Genetic Engineering And Biotechnology | Date: 2016-03-22
The present invention relates to an extract of Cissampelos pareira, its pharmaceutical compositions, and its therapeutic use in the prevention and treatment of dengue. It also relates to processes for the preparation of these extracts.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE.2012.3.5-04 | Award Amount: 7.76M | Year: 2012
The project GRACE will a) elaborate and sustainably implement a transparent framework for the review of GMOs or GM food and feed effects on environment, socio-economics and health and b) reconsider the design, execution and interpretation of results of animal feeding trials as well as in vitro studies for assessing the safety of GM food and feed. The framework will create high quality reviewing processes for different fields of GMO impact assessment and address the need for a well documented, transparent and sustainable representation of these reviewing processes. This will provide valuable and accessible information addressing the main issues associated with GMOs and enabling risk assessors, managers, scientists and the general public to reiterate and update their evaluations and conclusions on GMOs. It will adapt recently elaborated methodologies for (systematic) reviewing of the risk assessment information of GMOs and derived food and feed. The quality assessment for all reviewed papers and studies as well as the reviews conducted by the consortium, will be referenced by an open access database and one-stop-shop for data and information relevant to GMO risk assessment. Animal feeding trials and in vitro studies will clarify and compare the scientific added value of 90day feeding trials with whole foods with advanced state-of-the-art analytical, in vitro and in-silico tools. Suitable animal GMO-feeding models will be investigated, that are based on European (EFSA) and international guidance, and the project will provide guidance for relevant, alternative in vitro cell-based approaches for specific topics within the overall food and feed safety assessment. Available standard or scientifically approved protocols form the basis of the investigations also in the case of the analytical, in-vitro and second in-silico approaches. GRACE will provide guidance for the use and improvement of existing and suggested assessment tools in the field of food and feed safety.
Buratti E.,International Center for Genetic Engineering and Biotechnology |
Baralle F.E.,International Center for Genetic Engineering and Biotechnology
Trends in Biochemical Sciences | Year: 2012
Since the discovery that 43 kDa TAR DNA binding protein (TDP-43) is involved in neurodegeneration, studies of this protein have focused on the global effects of TDP-43 expression modulation on cell metabolism and survival. The major difficulty with these global searches, which can yield hundreds to thousands of variations in gene expression level and/or mRNA isoforms, is our limited ability to separate specific TDP-43 effects from secondary dysregulations occurring at the gene expression and various mRNA processing steps. In this review, we focus on two biochemical properties of TDP-43: its ability to bind RNA and its protein-protein interactions. In particular, we overview how these two properties may affect potentially very important processes for the pathology, from the autoregulation of TDP-43 to aggregation in the cytoplasmic/nuclear compartments. © 2012 Elsevier Ltd.
Gonzalez J.F.,International Center for Genetic Engineering and Biotechnology |
Venturi V.,International Center for Genetic Engineering and Biotechnology
Trends in Plant Science | Year: 2013
Extensive communication is believed to occur between eukaryotes and prokaryotes via signaling molecules; this field of research is now called interkingdom signaling. Recently, it has been discovered that many different plant-associated bacteria possess a protein closely related to the quorum-sensing (QS) LuxR-family protein that binds and responds to plant compounds. This LuxR protein does not have a cognate N-acyl homoserine lactone (AHL) signal synthase and therefore is regarded as a 'solo' or 'orphan'. The protein is involved in interkingdom signaling in rhizobia, xanthomonads, and pseudomonads, regulating processes important for plant-bacteria interaction. In this review, we focus on this new interkingdom signaling circuit, which is widespread among pathogenic and beneficial plant-associated bacteria. © 2012 .
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2015 | Award Amount: 328.50K | Year: 2016
Finding a CURE for 35 Million individuals living with HIV/AIDS is one of the great global health challenges of the 21st century. The major obstacle to HIV eradication is the persistence of latent HIV cellular reservoirs, where the integrated viral genome is transcriptionally silenced but replication-competent and can escape both Anti-Retroviral Therapy and Immune Responses. The development of novel strategies aimed at eliminating these reservoirs have become paramount in HIV research, if we want to achieve an HIV/AIDS CURE. To accelerate the State of the Art in HIV CURE research in Europe, our EU4HIVCURE consortium brings together an intersectoral and interdisciplinary collaboration between 3 Universities, 3 Hospitals, 1 International Research Organisation from 4 European countries and 1 University from Canada. Our aim is to dissect the intricate mechanisms controlling HIV-1 latency and identify new druggable targets to develop novel latency-reversing strategies and eradicate persistent viral reservoirs by forcing HIV-1 gene expression. To facilitate continuum for translation to the clinic, we have developed an operational framework, which maximises exchange of knowledge and expertise via secondements, networking and training activities.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: H2020-TWINN-2015 | Award Amount: 1.19M | Year: 2016
In 2013, the Science magazine announced Immunotherapy of cancer as the Breakthrough of the Year. The results of ongoing clinical studies with new cancer immunotherapeutics strongly support this enthusiasm. Following the lead of the top research groups, the Coordinator of the present proposal, Medical University of Warsaw (MUW) displays a predominant ambition of becoming a major player in the thriving area of Immuno-Oncology. MUW is one of the leading centres of competence in the Oncology field in Poland and presents a robust desire for further improvement of its excellence merits. Therefore, the main concept of the STREAM proposal is to bring together the high-level European research organizations with synergistic scientific and innovative expertise in the field of Immuno-Oncology, in order to establish an international, long-term, strategic partnership with MUW. The main model of the STREAM proposal is to foster enhanced scientific dialogue and twinning between MUW and four outstanding research centres via trans-national visits of scientific personnel, joint organization of a summer school and workshops, as well as promoting the active participation of STREAM researchers in the prestigious scientific conferences. Within the duration of the current project we intend to significantly enrich MUWs, regional and national quality profile regarding all of the variables of Composite indicator of Research Excellence in the Immuno-Oncology area. We will also set a new standard for conducting bioresearch and innovative thinking in Poland. We expect that the scale, ambition, and innovative character of the proposed project will bring the MUWs excellence to a new level - internationally recognized and competitive, in order to contribute to the well-being of the society and knowledge-based economy of Poland and EU. Our proposal provides an exceptional occasion to achieve real impact on human health, quality of life and economic status in the new area of enlarged Europe.
Agency: European Commission | Branch: FP7 | Program: MC-IEF | Phase: FP7-PEOPLE-2013-IEF | Award Amount: 93.71K | Year: 2014
BACKGROUND: There is a tremendous need to develop novel therapies for heart failure. In particular, sustained pathological hypertrophy, a major predictor of this condition, is a complex process, which involves transcriptional and posttranscriptional regulation of the cardiac genome. There is now clear indication that, besides a few known transcriptional regulators, multiple, still poorly understood cardiac factors are involved in hypertrophy; understanding this complexity is expected to pave to the way to innovative therapies. In particular, recent data demonstrate that dysregulated microRNAs (miRs) are associated with heart failure, and that selective modulation of miRs can provide therapeutic benefits. Our pilot-data show that expression of the miR-106b~25 cluster decreases during pathological hypertrophy in mice and that virus-mediated overexpression of this cluster prevents phenylephrine-induced hypertrophic remodeling. Following bioinformatics screens for potential direct downstream targets of the miR-25~106b cluster, we identified a series of transcription factors, which might play a role in pathological cardiac remodeling. AIM: To define the functional implication of the miR-106b~25 cluster in pathological cardiac hypertrophy and to exploit this information towards the development of novel therapeutic approaches. APPROACH: We will identify direct downstream targets of the miR-106b~25 cluster during hypertrophy, by performing Ago2-Immunoprecipitation and by treating neonatal cardiomyocytes with precursors of miR-25, miR-93 and miR-106b, followed by next generation sequencing (Objective 1); We aim to reverse pathological cardiac remodeling and prevent heart failure by delivery of recombinant adeno-associated virus (rAAV9)- miR-106b~25 in mice (Objective 2). The results obtained will generate important intellectual property value and will constitute the basis for further development towards the generation of novel therapies against heart failure.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: ISSI-5-2015 | Award Amount: 3.50M | Year: 2016
STAR BIOS 2 (Structural Transformation to Attain Responsible BIOSciences),coordinated by the University of Tor Vergata (IT), has been designed to respond to the Topic ISSI 5 (Workprogramme Science With And For Society). The general aim of project is that of contributing to the advancement of the Responsible Research and Innovation (RRI) strategy, which underpins Horizon 2020, by promoting 6 Action Plans (APs) oriented to attain a RRI structural change in research institutions from Europe and developing 3 further APs in non-european entities, all active in the field of biosciences. This strategy is geared to cope more in general with one of the main risk, for European research, i.e., its inadequate connection with society, by promoting its increasing alignment, in terms of both process and outcomes, with the needs and values of European society. This entails, in the RRI perspective, an increasing involvement of stakeholders at any level of the research and innovation process. The project has three main focuses: 1) Develop RRI-oriented structural change processes in the already mentioned institutions involved in biosciences research. This aim will be pursued through designing, implementing and evaluating RRI Action Plans. In order to secure the results emerging from the APs, a sustainability strategy will be developed and implemented during the project lifespan. APs will be supported by a central technical assistance and the project will be monitored and assessed. 2) Develop a learning process concerning: a) resistances and barriers to RRI (which are they, how they manifest themselves, which impact they have, etc.); b) key factors favouring or supporting RRI; c) strategic options and RRI-oriented tools. 3) Develop a sustainable model for RRI in biosciences.